Linked Life Data

9627182

Source:http://linkedlifedata.com/resource/pubmed/id/9627182

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1998-7-28
pubmed:abstractText
We determined the effect of nefiracetam, a novel cognitive enhancer, on the extracellular acetylcholine (ACh) level in the frontal cortex of freely moving rats, using a microdialysis technique without an acetylcholinesterase inhibitor in the perfusate. Treatment with nefiracetam (10 mg/kg, p.o.) produced a significant increase in the level of ACh in the brain dialysate, compared with the vehicle-treated group. This enhancing effect was also observed when the ACh level was elevated by administration of scopolamine (1 mg/kg, i.p.) at 45 min after the treatment with nefiracetam. In addition, perfusion of nefiracetam at the concentration of 10 microM significantly increased the extracellular ACh level in the frontal cortex of basal forebrain (BF)-lesioned rats, in which a marked decrease of the basal ACh level was observed in this region. These results suggest that enhancement of cortical ACh release by nefiracetam may contribute to an anti-amnesic effect on the learning deficits induced by treatment of scopolamine or BF-lesion in rats.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0304-3940
pubmed:author
pubmed:issnType
Print
pubmed:day
24
pubmed:volume
246
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
69-72
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study.
pubmed:affiliation
New Product Research Laboratories III, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan.
pubmed:publicationType
Journal Article